Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Express Scripts' Shares Got Slammed

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Prescription-drug benefits processor Express Scripts (Nasdaq: ESRX  ) should have taken a sick day today, as its shares lost as much as 18% before settling into a 12% loss as of this writing.

So what: Although Express Scripts beat earnings estimates by $0.03 per share, its revenue came in under projections by $500 million. This wasn't the cause of the drop, as Express Scripts analysts had some uncertainty as they adjusted to the company's acquisition of rival drug-benefits company Medco Health Solutions. The big news was CEO George Paz claiming that forward expectations for next year might be too optimistic, in light of economic uncertainty heading into 2013.

The pessimistic prediction helped drag down CVS Caremark (NYSE: CVS  ) , one of its most important partners. CVS had a strong report today as well, beating estimates on top and bottom lines and boosting its full-year forecast, but its shares were essentially flat this afternoon.

Now what: Investors never want to hear that their expectations for their stocks are too high, but this sounds like an indicator of broad economic weakness, rather than simply a problem with Express Scripts alone. However, Express Scripts' P/E is still a bit far from bargain territory, and with the company delaying full-year projections for 2013 to next February, it seems that the best thing for potential investors to do is be patient and dig deeper.

Want more news and updates? Add Express Scripts to your watchlist now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2098495, ~/Articles/ArticleHandler.aspx, 10/25/2016 2:53:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 18,223.03 77.32 0.43%
S&P 500 2,151.33 10.17 0.47%
NASD 5,309.83 52.43 1.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 4:00 PM
ESRX $69.80 Up +0.19 +0.27%
Express Scripts CAPS Rating: *****
CVS $88.00 Up +0.59 +0.67%
CVS Health CAPS Rating: ****